 |
|
| RAPID REFERENCE TO SCHIZOPHRENIA
| |
| | |
|
|
 Rapid Reference Series
To order this title, and for more information, click here
By
Peter Jones, MSc, PhD, FRCP, MRCPsych, Professor of Psychiatry, University of Cambridge, Cambridge, UK
Peter Buckley, MD, MRCPsych, Professor and Chairman,
Department of Psychiatry and
Associate Dean for Leadership Development Medical College of Georgia, Georgia, USA
Included in series
Rapid Reference,
Description
Each title in the Rapid Reference series provides the reader with authoritative and accessible information from a clinical expert in the
field, to assist with treatment decisions. Each title includes standard core content (epidemiology, management, therapy) combined with
the additional information?such as FAQs and patient organizations?needed by the primary care practitioners to provide effective patient
care. The books also include drug listings, clinical trials, information on future developments, and web site listings, to keep the reader
up to speed with new developments and to extend their knowledge of the disease area.
Titles in the series focus on chronic conditions
seen most often in the primary care setting. With patients becoming better informed about the nature and management of their conditions,
Rapid Reference is a timely new series that offers the primary care practitioners easy access to the best information for patient care
and management.
Audience
Primary Care / Family Practice Practitioners and Residents, Physician Assistants, Nurse Practitioners
Contents
1. Introduction and Background
2. Definition and epidemiology
3. Aetiology
4. Diagnosis
5. Prevention
-reduction/removal
of risk factors
-enhanced prenatal care
-role of stress reduction
-reduction of secondary forms of schizophrenia (eg drug induced,
head trauma)
-(pre)detection of high risk patients and patients with childhood neurodevelopmental deviance
-prodromal detection
and early intervention strategies
6.Treatment
-pharmacological
-description of typical antipsychotics
-types
-mechanism(s)
of action
-efficacy
-onset
-overall
-negative symptoms
-depressive symptoms
-cognition
-hostility
-adverse effects
-motor-acute
extrapyramidal, tardive dyskinesia, neuroleptic malignant syndrome
-endocrine
-metabolic
-other
-description of atypical
antipsychotics
-concept and validity of atypicality
-mechanism(s) of action and relative receptor affinity profile of each atypical
antipsychotic
-clozapine
-efficacy
-onset
-overall
-negative symptoms
-depressive symptoms
-suicidality
-cognition
-hostility
-adverse
effects
-agranulocystosis
-seizures
-sedation
-drooling
-weight gain
-metabolic
-other
-risperidone
-efficacy
-onset
-overall
-negative
symptoms
-depressive symptoms
-cognition
-hostility
-adverse effects
-EPS
-sedation
-weight gain
-metabolic
-other
-olanzapine
-efficacy
-onset
-overall
-negative symptoms
-depressive symptoms
-cognition
-hostility
-adverse effects
-EPS
-sedation
-weight
gain
-metabolic
-other
-quetiapine
-efficacy
-onset
-overall
-negative symptoms
-depressive symptoms
-cognition
-hostility
-adverse
effects
-EPS
-cataracts
-sedation
-weight gain
-metabolic
-other
-ziprasidone
-efficacy
-onset
-overall
-negative
symptoms
-depressive symptoms
-cognition
-hostility
-adverse effects
-cardiotoxicity
-EPS
-sedation
-weight gain
-metabolic
-other
-description
of other antipsychotic medications which are under debate as to whether they are typical or atypical agents
-amisulpiride, sulpiride,
zotepine
-mechanism (s) of action
-efficacy
-description of other psychotropic medications which are used to augment the treatment
response to either typical or atypical antipsychotic agents
-nonpharmacological
-electroconvulsive therapy
-psychotherapies/psychosocial
rehabilitation
-individual supportive psychotherapy
-cognitive behavioral therapy
-cognitive remediation
-compliance therapy
-social
skills therapy
-assertive community treatment
-case management
-family therapy
-mental health services and systems of care
7.
Management
-domains of outcome, with emphasis on cognition
-acute psychotic episode
-first episode psychosis
-choice
of drug
-dosing strategies
-other aspects of care
-maintenance therapy
-initial choice of drug and sequential choice of agents
-dosing
and duration of treatment
-other aspects of care
-treatment refractory schizophrenia
-assessment
-sequential choice of agents
-dosing
and duration of treatment
-role of augmentation
-role of ECT
-other aspects of care
-comorbidities
8. Future developments
-drugs
which are under development
-new psychosocial approaches
-Evidence-Based-Medicine and schizophrenia
9. Frequently asked
questions
-is there a test for schizophrenia and can it be used to diagnose family members at risk?
-does drug use/abuse cause
schizophrenia?
-how violent are people with schizophrenia?
-if the illness is caught early can it be treated with a better outcome?
-how
long should a person be on medication?
-how do you choose the right medication and how do you know its the right one?
-how long
should you wait on one drug before switching to another drug?
-what is the best way of switching from one drug to another?
-what
is the best combination of treatment?
-are other treatments (eg herbals, vitamins, meditation) helpful for schizophrenia?
-how
do you convince a person with schizophrenia to comply with their treatment?
-if you suspect sombody has schizophrenia, who should
you contact to get help for them?
10. References
11. Appendices
Drug information
Useful addresses and websites
| Bibliographic details |
Paperback, 104 pages, publication date: DEC-2002
ISBN-13: 978-0-7234-3316-3
ISBN-10: 0-7234-3316-X
Imprint: MOSBY
|
062/612
Last update: 27 Sep 2008
|
|
| |
| | |
|
|
| |
